Multidrug resistance is one of the main obstacles in the chemotherapy of cancer. Its inhibition by combination of chemosensitizers with antitumor compounds is a very active field of research, since safe and potent reversal agents would be beneficial for clinical use. Most modulators act by binding to membrane transport proteins (specially P-gp and MRP) and inhibiting their drug-effluxing activity, or by indirect mechanisms related to phosphorylation of the transport proteins or expression of the mdr1 and mrp1 genes. The main body of the review focuses on the study of the known MDR modulators, which are classified according to their chemical structures. General structure-activity studies of this therapeutic group are hampered by the very heterogeneous chemical structure of the compounds, although some conclusions have been drawn from the study of homogeneous series of molecules.

Treatment of a variety of azoles or their anions with p-tolyllead triacetate in the presence of copper-(II) acetate afforded the corresponding IV-aryl derivatives, normally in excellent yields. Room temperature arylation of an aminobenzimidazole derivative was chemoselectively directed to the amino group.

No abstract

No abstract

No abstract